Jelena Vulevic has a PhD in Gut Microbiology and 20 years of experience in developing therapies based on microbiota in gut, immune and brain health. She has collaborated with some of World’s leading research and clinical centres and was involved in nearly 50 clinical studies. These included populations from infant to elderly, frail to obese, metabolic syndrome, diabetes, Clostridium difficile infection, IBS, IBD, cancer, schizophrenia and autism. Dr Vulevic has academic research experience having spent more than 11 years at the School of Chemistry, Food and Pharmacy at the University of Reading, UK. In February 2011 she moved to industry at Clasado Biosciences until June 2019 where she worked as Medical Liaison/Scientific Affairs Manager moving onto R&D as Manager and then to Head of R&D for the last last 2 years. She is adept at cross functional collaboration, interface with both clinical and commercial stakeholders and in identifying project issues/opportunities, management of budgets, projects and labs. Dr Vulevic has a proven track record of oral presentations and various publications ranging from peer reviewed to invited editorials and newspaper comments/interviews.
Did you know?
Miranda Wang and Jeanny Yao have an uncanny talent for finding value where others see waste. Their plastics upcycling company, Novoloop, just raised an $21m Series A to prove it.
To find the future of food, you may have to look no further than Emeryville, CA, a small city by the San Francisco Bay, where Upside Foods has built a 53,000-square-foot production facility for cultivated meat, the first of its kind.
In a timeless dilemma for new parents, Radhika and her husband Bharath discovered early that their baby daughter was a fussy sleeper. The situation left them tired and frustrated; being effective at work became a challenge.
The question for Sumit Sinha and Mukesh Bansal in February 2019 was which would come first: The funding for their seed round or the sale of their Hyundai hatchbacks.
In December 2021 Prellis raised a $14.5 million Series B and has signed partnerships with pharmaceutical behemoths including Bristol Myers Squibb and Sanofi.
It was 2016, and Chiu Chau was on the ropes. He had pitched nearly 150 venture capital firms. No one would invest. Everyone doubted the startup with the open-source laboratory robot.
Tesh Mbaabu rarely showed up to his freshman computer science class at the University of Nairobi. His classmate Mesongo Sibuti noticed.
Adebayo (“Ade”) Alonge and Amy Kao, co-founders of RxAll had nvented a handheld scanner for detecting counterfeit prescription drugs—an illicit, multibillion-dollar industry that kills an estimated 1 million people annually globally and 100,000 in Africa.